Upregulated WTAP expression in colorectal cancer correlates with tumor site and differentiation

Xiao-Fang Dong1*, Yan Wang1*, Chih-Hsin Tang2,3,4, Bi-Fei Huang5, Zhang Du6, Qian Wang5, Jun-Kang Shao5, Hua-Jun Lu7*, Chao-Qun Wang6*,

1 Department of Medical Oncology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China, 2 Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan, 3 Department of Pharmacology, School of Medicine, China Medical University, Taichung, Taiwan, 4 Department of Biotechnology, College of Health Science, Asia University, Taichung, Taiwan, 5 Department of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China, 6 Department of Anus and Intestine Surgery, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China, 7 Department of Oncological Radiotherapy, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China

* These authors contributed equally to this work.

Abstract

Few reports exist regarding the expression and function of Wilms' tumor 1-associated protein (WTAP) in colorectal cancer (CRC), and the evidence is controversial. Our analysis explored the expression of WTAP in CRC tissue, and analyzed its clinical and prognostic significance. WTAP expression was significantly higher in CRC tissue than in colorectal adenoma and normal colorectal tissue. WTAP was highest in left colon tumor samples and negatively associated with tumor differentiation, as well as depth of tumor invasion. In multiple logistic regression analysis, independent predictors of WTAP expression in CRC included tumor in the left colon (odds ratio = 2.634; 95% confidence interval: 1.129–6.142; \( P = 0.025 \)) and poorly differentiated tissue (0.072; 0.014–0.367; \( P = 0.002 \)). No clear relationship was observed between CRC patient prognosis and WTAP expression. We suggest that WTAP expression is upregulated in CRC, highly expressed in left colon cancer and negatively correlated with tumor differentiation.

Introduction

GLOBOCAN 2020 estimates of cancer incidence and mortality ranked colorectal cancer (CRC) as the third most commonly diagnosed cancer worldwide and the second leading cause of death [1]. Wilms’ tumor 1-associated protein (WTAP) is a key component of the human methyltransferase N6-methyladenosine (m6A) complex [2] and is implicated in the initiation and progression of various human cancers [2, 3]. Upregulated levels of WTAP expression facilitate the growth and progression of endometrial cancer via the caveolin-1 (CAV-1)/nuclear factor-κB (NF-κB) axis and are associated with worse survival outcomes [4]. Moreover,
WTAP overexpression promotes osteosarcoma tumorigenesis by suppressing homeobox-containing 1 (HMBOX1) expression [5] and is correlated with tumour-associated T lymphocyte infiltration in gastric cancer, indicating a poor prognosis [6]. WTAP also promotes the progression of hepatocellular carcinoma via the HuR-ETS proto-oncogene 1 (ETS1) axis [7], and the upregulation of WTAP in ovarian cancer [8] and bladder cancer [9] is associated with poor prognosis.

WTAP expression and function in CRC is controversial. Evidence suggests that WTAP is an oncogene. For example, the tumour suppressor carbonic anhydrase IV (CA4) inhibits colon cancer development by targeting the WTAP-WT1-TBL1 axis to inhibit Wnt signaling [10]. Furthermore, WTAP is upregulated in CRC tissues compared with normal tissues [11] and is highly expressed in poorly differentiated CRC tissues [12], while oncogene β-arrestin2 (Arrb2) promotes the growth and migration of CRC cells by upregulating WTAP expression [13]. However, in an analysis of records from three databases containing information on associations between human WTAP gene expression and CRC prognosis, poor survival was associated with reduced WTAP expression in two databases, while increased WTAP expression was associated with poor survival in the remaining database [14]. Thus, further research is needed to better understand the expression and function of WTAP in CRC.

In this study, we performed immunohistochemical (IHC) analysis to detect WTAP expression in CRC and colorectal adenoma tissue samples obtained from a cohort of Chinese patients. We aimed to clarify the expression of WTAP in CRC and its clinicopathological and prognostic significance.

Materials and methods

Patients and tissue samples

Tissue samples were obtained from 375 Chinese patients with CRC (median 69 [range 24–94] years) and 58 patients with colorectal adenoma (median 67 [37–88] years) who underwent primary surgical treatment at the Affiliated Dongyang Hospital of Wenzhou Medical University (Dongyang, Zhejiang, China) between 2008 and 2015. Eighty-one adjacent normal colorectal tissue specimens were obtained from the above-mentioned 81 CRC samples post-surgery. We conducted this study at 2020–2021. During or after data collection, authors can access to information that could identify individual participants. Clinicopathological characteristics were determined for all study participants based on their medical records (see Table 2). Pathohistological and clinical diagnoses satisfied the World Health Organization classification of tumours of the digestive system [15, 16]. CRC patients were staged according to the eighth edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual [17]. Follow-up information was available for 258 CRC patients at a median 60 months of follow-up (range 11–60 months). This study was reviewed and approved by the Ethics Committee of the Affiliated Dongyang Hospital of Wenzhou Medical University (2020-YX-063), Dongyang, China. Written informed consent was obtained from all these patients or their guardians. All study methods satisfied the relevant guidelines and regulations issued by the Affiliated Dongyang Hospital of Wenzhou Medical University.

Tissue array preparation

We followed the methods described by Wang et al., 2020 [18]. The Quick-Ray® UT-06 (Unitma Co., Ltd., Seoul, Korea) tissue microarray system was used to prepare tissue specimens, and we used the Quick-Ray premade recipient block (UB-06) wax model. Three representative sites from each CRC tissue were selected for sampling, and a tissue array with a diameter of 1 mm was made following the manufacturer’s protocol.
IHC analysis

IHC staining of paraffin-embedded tissue sections used the Envision System (Dako, Glostrup, Denmark), as described previously [19, 20]. The primary antibody was anti-WTAP rabbit monoclonal antibody (clone EPR18744, diluted at 1:3200; Abcam, Cambridge, England). The secondary antibody was Dako’s HRP rabbit/mouse universal antibody (Dako, Glostrup, Denmark). The negative control was incubated with vehicle then with secondary antibody, without primary antibody.

Assessment of staining

WTAP staining in colorectal tissues was practically uniform throughout all tumor cells, so we needed to only evaluate WTAP staining intensity. The intensity of nuclear staining for WTAP was assessed in CRC tissue and scored on a 4-point scale from 0 (negative) to 1 (weak), 2 (moderate), or 3 (strong) [21–24]. High WTAP expression was defined as a staining intensity of positive invasive cancer cells of 2 or 3 [22, 24]. Each entire section was scanned and scored independently by two pathologists.

Patient follow-up

We followed the methods described by Wang et al., 2020 [18].

Statistical analysis

Statistical analyses were conducted using SPSS software version 19.0 (SPSS Inc, Chicago, IL, USA). Between-group differences in WTAP expression were compared using a Pearson’s chi-square test for qualitative variables. Independent correlation factors of WTAP expression were assessed by multivariate logistic regression analysis. Relapse-free survival (RFS) and overall survival (OS) rates were estimated by the Kaplan-Meier method and compared using log-rank testing. \( P < 0.05 \) was considered to be statistically significant.

Results

Expression of WTAP in CRC tissue and its relationship with clinicopathological characteristics

WTAP was expressed in the nuclei of CRC cells. The proportion of high WTAP expression in CRC tissue specimens was 80.8% (303/375), compared with 22.4% (13/58) of colorectal adenoma tissues and 19.8% (16/81) of normal colorectal tissue specimens; the expression of WTAP in CRC was significantly higher than that in colorectal adenoma and normal tissue \( (P < 0.001) \) (Table 1).

As shown in Table 2, high WTAP expression was identified in 88.4% (76/86) of left colon cancer tissue, in 81.7% (161/197) of rectal cancer tissue and in 71.7% (66/92) of right colon

| Group                | No.  | WTAP expression          |
|----------------------|------|--------------------------|
|                      |      | Low expression, n (%)    | High expression, n (%) |
| Normal colorectal    | 81   | 65 (80.2%)               | 16 (19.8%)             |
| Colorectal adenomas  | 58   | 45 (77.6%)               | 13 (22.4%)             |
| Colorectal cancer    | 375  | 72 (19.2%)               | 303 (80.8%)*           |

\* \( P < 0.001 \).
The rate of WTAP expression in poorly differentiated CRC tissue (53.5%, 23/43) was significantly lower than that of moderately differentiated (83.0%, 244/294) and highly differentiated CRC tissue (94.7%, 36/38) \((P < 0.001)\) (Fig 1). In regard to the depth of invasion, the rate of high WTAP expression was significantly lower in the T4 group (75.5%, 123/163) compared with the T3 group (81.9%, 118/144), T2 group (90.9%, 50/55) and Tis+T1 group (92.3%, 12/13) \((P = 0.049)\). In logistic regression multivariate analysis, independent predictors of WTAP expression in CRC included left colon tumor site (odds ratio = 2.634; 95% confidence interval: 1.129–6.142; \(P = 0.025\)) and poorly differentiated tumor (0.072; 0.014–0.367; \(P = 0.002\)).

No association between WTAP expression and survival of patients with CRC

To assess the potential impact of WTAP expression on survival of CRC patients, we analyzed WTAP expression in relation to RFS and OS rates. Five-year RFS and OS rates were 67.4% and 77.1%, respectively. As shown in Fig 2, no associations were observed between WTAP expression and survival. The 207 patients with high levels of WTAP expression had a mean RFS of 48.8 months and an estimated 5-year RFS rate of 67.6%; corresponding values in the 51
patients whose tumors expressed low levels of WTAP were 48.0 months and 66.7%, respectively ($P = 0.867$; Fig 2A). Mean OS was 54.3 months (with an estimated 5-year OS rate of 77.8%) in the patients with high levels of WTAP expression and 52.9 months (with an estimated 5-year OS rate of 74.5%) in those with low levels of WTAP ($P = 0.587$; Fig 2B).

We analyzed the effect of WTAP expression on the prognosis of right colon cancer, left colon cancer or rectal cancer. As shown in Fig 2C–2H, whether in right colon cancer (Fig 2C and 2D), left colon cancer (Fig 2E and 2F) or rectal cancer (Fig 2G and 2H), the prognosis of tumors that were high WTAP expression did not differ significantly from that of low WTAP group.

**Discussion**

Several studies have reported upregulation of WTAP in malignant tumors and the finding that WTAP acts as an oncogene, promoting cancer occurrence and development [4–9]. Results of
investigations into the expression and role of WTAP in CRC are controversial. Whereas some studies have shown that WTAP plays an oncogenic role in CRC [10–13], evidence has also shown that reduced WTAP expression is associated with poor survival [14]. Moreover, no research exists regarding the expression and clinical significance of WTAP in large-scale samples of CRC tissue.

Our findings revealed significantly upregulated WTAP expression in CRC tissue compared with colorectal adenoma and normal colorectal tissue, indicating that WTAP may be involved in the occurrence of CRC. Liu et al [11] reported finding abundant WTAP expression in colon cancer but not in rectal cancer, but their study only included 22 colon cancer tissue specimens and 21 rectal cancer specimens, and did not further subdivide the left and right colon tumors. In our study, we found that WTAP expression was highest in left colon tumor samples, and
the left colon is an independent factor affecting WTAP expression. Evidence shows that tumors arising from right colon, left colon, and rectum each have different biological and molecular features [25–27]. Patients with right colon cancer were more likely to be diagnosed with a more advanced stage and to have more poorly differentiated tumors [25]. Since WTAP expression decreases in higher-stage and poorly differentiated tumors, it makes sense that WTAP expression is lower in right colon cancer. Microsatellite instability-high (MSI-H), deficiency of mismatch repair genes, KRAS and BRAF mutations, and CpG island methylation are more common in right colon cancer than that in left colon cancer [28–32]. Whether the high expression of WTAP in left colon cancer is related to these molecular characteristics needs further study. Wang et al [12] detected the expression of WTAP mRNA and they reported finding high WTAP expression in poorly differentiated tissues, but their study was also limited by the small number of samples (10 matched pairs of poorly differentiated and highly differentiated CRC tissue samples). Our study included 375 CRC tissue samples and found that WTAP protein expression negatively correlated with differentiation of the tumor, and that WTAP protein expression is lowest in poorly differentiated tumors. Further analysis showed that poorly differentiated tumors are independently negatively correlated with WTAP expression. We suspect that the expression of WTAP may be inhibited in poorly differentiated CRC; the molecular mechanism needs to be elucidated. Coupled with the established fact that poorly differentiated tumors are associated with higher aggressiveness [15], finding lower WTAP expression in poorly differentiated tumors makes sense that WTAP expression is lower in samples with deeper tumor invasion. According to the above, upregulated WTAP expression in CRC is positively correlated with left colon tumors and negatively correlated with poorly differentiated tumors.

Our survival analysis failed to reveal any association between WTAP expression and survival, which we speculate could be because the oncogenic functions of WTAP are counterbalanced by the suppression of WTAP expression in poorly differentiated tumors. However, in an analysis of records from three databases have shown that poor survival was associated with reduced WTAP expression in two databases, while increased WTAP expression was associated with poor survival in the remaining database [14]. We speculate that these varying results can ascribe to demographic or cohort-specific differences. More research is needed to determine how WTAP exerts oncogenic functions and to clarify the molecular mechanisms underlying its negative correlation with poorly differentiated tumors. Such clarification may enable the manipulation of CRC cell differentiation, and is important for future considerations surrounding the use of WTAP in the inhibition of CRC.

Supporting information
S1 Table. Expression of WTAP in CRC tissue.
(XLS)

S2 Table. Expression of METTL3/14 in CRC tissue.
(XLS)

Acknowledgments
We would like to thank Iona J. MacDonald from China Medical University for her English language revision of this manuscript.

Author Contributions
Conceptualization: Xiao-Fang Dong, Yan Wang, Hua-Jun Lu, Chao-Qun Wang.
Data curation: Yan Wang, Hua-Jun Lu, Chao-Qun Wang.

Funding acquisition: Chao-Qun Wang.

Methodology: Yan Wang, Qian Wang, Chao-Qun Wang.

Resources: Xiao-Fang Dong, Bi-Fei Huang, Zhang Du, Jun-Kang Shao.

Writing – original draft: Chao-Qun Wang.

Writing – review & editing: Chih-Hsin Tang.

References

1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., et al, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: a cancer journal for clinicians, (2021).

2. Liu J., Yue Y., Han D., Wang X., Fu Y., Zhang L., et al, A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation, Nature chemical biology, 10 (2014) 93–95. https://doi.org/10.1038/nchembio.1432 PMID: 24316715

3. Shi H., Wei J., He C., Where, When, and How: Context-Dependent Functions of RNA Methylation Writers, Readers, and Erasers, Molecular cell, 74 (2019) 640–650. https://doi.org/10.1016/j.molcel.2019.04.025 PMID: 31100245

4. Li Q., Wang C., Dong W., Su Y., Ma Z., WTAP facilitates progression of endometrial cancer via CAV-1/ NF-kappaB axis, Cell biology international, (2021). https://doi.org/10.1002/cbin.1432 PMID: 33559954

5. Chen S., Li Y., Zhi S., Ding Z., Wang W., Peng Y., et al, WTAP promotes osteosarcoma tumorigenesis by repressing HMBOX1 expression in an m(6)A-dependent manner, Cell death & disease, 11 (2020) 659.

6. Li H., Su Q., Li B., Lan L., Wang C., Li W., et al, High expression of WTAP leads to poor prognosis of gastric cancer by influencing tumour-associated T lymphocyte infiltration, Journal of cellular and molecular medicine, 24 (2020) 4422–4465. https://doi.org/10.1111/jcmm.15104 PMID: 32176425

7. Chen Y., Peng C., Chen J., Chen D., Yang B., He B., et al, WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1, Molecular cancer, 18 (2019) 127. https://doi.org/10.1186/s12943-019-1053-8 PMID: 31439691

8. Yu H.L., Ma X.D., Tong J.F., Li J.Q., Guan X.J., Yang J.H., WTAP is a prognostic marker of high-grade serous ovarian cancer and regulates the progression of ovarian cancer cells, Oncotargets and therapy, 12 (2019) 6191–6201. https://doi.org/10.2147/OTT.S208730 PMID: 31496724

9. Chen L., Wang X., Relationship between the genetic expression of WTAP and bladder cancer and patient prognosis, Oncology letters, 16 (2018) 6966–6970. https://doi.org/10.3892/ol.2018.9554 PMID: 30546429

10. Zhang J., Tsai H., Li X., Wang H., Gao J., Wang K., et al, Carbonic anhydrase IV inhibits colon cancer development by inhibiting the Wnt signalling pathway through targeting the WTAP-WT1-TBL1 axis, Gut, 65 (2016) 1482–1493. https://doi.org/10.1136/gutjnl-2014-306814 PMID: 26071322

11. Liu X., Liu L., Dong Z., Li J., Yu Y., Chen X., et al, Expression patterns and prognostic value of m(6)A-related genes in colorectal cancer, American journal of translational research, 11 (2019) 3972–3991. PMID: 31396313

12. Wang S., Fan X., Zhu J., Xu D., Li R., Chen R., et al, The differentiation of colorectal cancer is closely related to m6A modification, Biochemical and biophysical research communications, 546 (2021) 65–73. https://doi.org/10.1016/j.bbrc.2021.02.001 PMID: 33571906

13. Liang H., Lin Z., Ye Y., Luo R., Zeng L., ARRB2 promotes colorectal cancer growth through triggering WTAP, Acta biochimica et biophysica Sinica, 53 (2021) 85–93. https://doi.org/10.1093/abbs/gmaa151 PMID: 33387479

14. Wu L.S., Qian J.Y., Wang M., Yang H., Identifying the role of Wilms tumor 1 associated protein in cancer prediction using integrative genomic analyses, Molecular medicine reports, 14 (2016) 2823–2831. https://doi.org/10.3892/mmr.2016.5528 PMID: 27430156

15. Bosman FT C. F., Hruban RH, Theise ND, WHO classification of tumours of the digestive system, Fourth Edition, Lyon: IARC Press 2010.

16. Nagtaga I.D., Odze R.D., Klimstra D., Paradis V., Rugge M., Schirmacher P., et al, W.H.O.C.o.T.E. Board, The 2019 WHO classification of tumours of the digestive system, Histopathology, 76 (2020) 182–188. https://doi.org/10.1111/his.13975 PMID: 31433515
17. Amin M.B., Greene F.L., Edge S.B., Compton C.C., Gershenwald J.E., Brookland R.K., et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging, CA: a cancer journal for clinicians, 67 (2017) 93–99. https://doi.org/10.3322/caac.21388 PMID: 28094848

18. Wang C.Q., Wang Y., Huang B.F., Tang C.H., Du Z., Zeng Y., et al. High Expression of Both Resistin and Fascin-1 Predicts a Poor Prognosis in Patients with Colorectal Cancer, BioMed research international, 2020 (2020) 8753175. https://doi.org/10.1155/2020/8753175 PMID: 32420377

19. Wang C.Q., Tang C.H., Chang H.T., Li X.N., Zhao Y.M., Su C.M., et al. Fascin-1 as a novel diagnostic marker of triple-negative breast cancer, Cancer medicine, 5 (2016) 1983–1988. https://doi.org/10.1002/cam4.746 PMID: 27184764

20. Wang C.Q., Li Y., Huang B.F., Zhao Y.M., Yuan H., Guo D., et al. EGFR conjunct FSCN1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer, Scientific reports, 7 (2017) 15654. https://doi.org/10.1038/s41598-017-15939-9 PMID: 29142206

21. Zeng Y., Tang C.H., Wang Y., Lu H.J., Huang B.F., Wang Q., et al. Combined High Resistin and EGFR Expression Predicts a Poor Prognosis in Breast Cancer, BioMed research international, 2020 (2020) 8835398. https://doi.org/10.1155/2020/8835398 PMID: 33313320

22. Dong X.F., Wang Y., Huang B.F., Hu G.N., Shao J.K., Wang Q., et al. Downregulated METTL14 Expression Correlates with Breast Cancer Tumor Grade and Molecular Classification, BioMed research international, 2020 (2020) 8823270. https://doi.org/10.1155/2020/8823270 PMID: 33134390

23. Wang C.Q., Tang C.H., Tzeng H.E., Jin L., Zhao J., Kang L., et al. Impacts of RETN genetic polymorphism on breast cancer development, Journal of Cancer, 11 (2020) 2769–2777. https://doi.org/10.7150/jca.38086 PMID: 3226495

24. Wang C.Q., Huang B.F., Wang Y., Tang C.H., Jin H.C., Shao F., et al. Subcellular localization of HMGB1 in colorectal cancer impacts on tumor grade and survival prognosis, Scientific reports, 10 (2020) 18587. https://doi.org/10.1038/s41598-020-75783-2 PMID: 33122771

25. Weiss J.M., Pfau P.R., O’Connor E.S., King J., LoConte N., Kennedy G., et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results—Medicare data, Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 29 (2011) 4401–4409.

26. Powell A.G., Wallace R., McKee R.F., Anderson J.H., Going J.J., Edwards J., et al. The relationship between tumour site, clinicopathological characteristics and cancer-specific survival in patients undergoing surgery for colorectal cancer, Colorectal disease: the official journal of the Association of Coloproctology of Great Britain and Ireland, 14 (2012) 1493–1499. https://doi.org/10.1111/j.1463-1318.2012.03048.x PMID: 22507826

27. Takahashi Y., Sugai T., Habano W., Ishida K., Eizuka M., Otsuka K., et al. Suzuki, Molecular differences in the microsatellite stable phenotype between left-sided and right-sided colorectal cancer, International journal of cancer, 139 (2016) 2493–2501. https://doi.org/10.1002/ijc.30377 PMID: 27509333

28. Tran B., Kopetz S., Tie J., Gibbs P., Jiang Z.Q., Lieu C.H., et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer, Cancer, 117 (2011) 4623–4632. https://doi.org/10.1002/cncr.26086 PMID: 21456008

29. Hutchins G., Southward K., Handley K., Magill L., Beaumont C., Stahlschmidt J., et al. The value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer, Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 29 (2011) 1261–1270.

30. Shimada Y., Kameyama H., Nagahashi M., Ichikawa H., Muneoka Y., Yagi R., et al. Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer, Oncotarget, 8 (2017) 93567–93579. https://doi.org/10.18632/oncotarget.20510 PMID: 29212173

31. Tokunaga R., Xu J., Johnston C., Goldberg R.M., Philip P.A., Seeber A., et al. Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer, Clinical cancer research: an official journal of the American Association for Cancer Research, 25 (2019) 3096–3103. https://doi.org/10.1158/1078-0432.CCR-18-3388 PMID: 30692096

32. Shen H., Yang J., Huang Q., Jiang M.J., Tan Y.N., Fu J.F., et al. Different treatment strategies and molecular features between right-sided and left-sided colon cancers, World journal of gastroenterology, 21 (2015) 6470–6478. https://doi.org/10.3748/wjg.v21.i21.6470 PMID: 26074686